A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With β-Thalassemia
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Luspatercept (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- Sponsors Acceleron Pharma
- 17 Jun 2021 Results analyzing MCV variation as an early predictor of response to Luspatercept by using data from phase II/III clinical trials (NCT01749540, NCT02268409, NCT02604433, NCT03342404, NCT04064060) presented at the 26th Congress of the European Haematology Association
- 12 Jul 2020 Data from patients with beta-thalassemia in 3 studies (NCT01749540, NCT02268409, NCT02604433) assessing population pharmacokinetics and exposure-response relationship of luspatercept in patients with beta-thalassemia under a titration-to-response dosing regimen published in the Journal of Clinical Pharmacology
- 10 Jan 2019 According to an Acceleron Pharma media release, the journal Blood has published results from this trial. Antonio Piga was a lead author of the newly published study.